EICHORPublic-registry site landscape for NCT05703971, “Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients”, a Small Cell Lung Cancer Extensive Stage study sponsored by Genprex, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT05703971 (registry record) |
| Study title | Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients |
| Official title | A Phase 1/2 Clinical Trial of Quaratusugene Ozeplasmid and Atezolizumab Maintenance Therapy in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) |
| Sponsor | Genprex, Inc. |
| Condition(s) | Small Cell Lung Cancer Extensive Stage |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 17 |
| Intervention(s) | quaratusugene ozeplasmid, atezolizumab |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT05703971.
Eichor generates a preliminary site-risk snapshot for NCT05703971 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
